Drugs Made In America Acquisition reported net income of $4.40M for the quarter ended Jun 2026. This income statement covers 4 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 14.38M | 15.57M | 26.11M | 63.70M |
| Operating items | ||||
| Selling, General & AdministrativeSG&A | 0.16M | 0.24M | 0.11M | |
| Operating ExpensesOpex | 0.16M | 0.24M | 0.11M | |
| Operating IncomeOp. Inc | -0.16M | -0.24M | -0.11M | |
| EBIT | -0.16M | -0.24M | -0.11M | |
| Non-operating items | ||||
| Interest & Investment IncomeInt & Inv Inc | 0.11M | 4.82M | 4.51M | |
| Non Operating IncomeNon Op. Inc. | 0.11M | 4.57M | 4.51M | |
| Net income details | ||||
| EBT | -0.05M | 4.59M | 4.40M | |
| Profit After TaxPAT | -0.05M | 4.33M | 4.40M | |
| Income from Continuing OperationsIncome (Continuing) | -0.05M | 4.59M | 4.40M | |
| Consolidated Net IncomeConsol Net Inc. | -0.05M | 4.59M | 4.40M | |
| Income towards Parent CompanyParent Net Inc | -0.05M | 4.59M | 4.40M | |
| Net Income towards Common StockholdersNet Income | -0.04M | 2.26M | 3.45M | |
| Additional items | ||||
| EPS (Basic) | 0.00 | 0.09 | 0.05 | |
| EPS (Diluted) | 0.00 | 0.08 | 0.05 | |
| Shares Outstanding | 12.50M | 15.28M | 26.11M | 63.70M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 12.50M | 17.16M | 27.71M | 63.70M |
| EBITDA | -0.16M | -0.24M | -0.11M |